SCHEMBL10314541

SCHEMBL10314541

Cc1cc2sc(C=O)c(O)c2c(=O)n1CC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPT P10636 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ GAA P10253 3/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ BLM P54132 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ THRB P10828 1/20 0.37
▸ PDE4B Q07343 2/20 0.37
▸ HRH1 P35367 1/20 0.36
▸ GPR35 Q9HC97 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314566 0.86 LMNA (0.47) LMNAHSD17B10MAPTKMT2AGAA
SCHEMBL10314601 0.84 LMNA (0.45) LMNAHSD17B10MAPTKMT2AGAA
SCHEMBL3401272 0.84 LMNA (0.51) LMNAHSD17B10MAPTKMT2AGAA
SCHEMBL1062879 0.80 KMT2A (0.47) LMNAMAPTKMT2AGAAMEN1
SCHEMBL10314579 0.76 LMNA (0.50) LMNAMAPTKMT2AGAAMEN1
SCHEMBL10314563 0.76 LMNA (0.49) LMNAHSD17B10MAPTKMT2AGAA
SCHEMBL1057594 0.75 LMNA (0.48) LMNAHSD17B10MAPTKMT2AGAA
SCHEMBL1061528 0.73 LMNA (0.47) LMNAHSD17B10MAPTKMT2AGAA
SCHEMBL10314589 0.73 KMT2A (0.41) LMNAMAPTKMT2AGAAMEN1
SCHEMBL10314639 0.72 LMNA (0.56) LMNAHSD17B10MAPTKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 LMNA 4392/4885HSD17B10 222/4885MAPT 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback